In the FAST study, the addition of zolbetuximab to EOX significantly prolonged median progression-free survival and median overall survival in the overall patient population and the subgroup of patients with tumors expressing CLDN18.2 in ≥ 70% of tumor cells [12]. The gene discussed is CLDN18; the disease is neoplasm.